会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME
    • 包含HMG-COA还原酶和阿司匹林抑制剂的组合制剂及其制造方法
    • WO2009022821A2
    • 2009-02-19
    • PCT/KR2008/004623
    • 2008-08-08
    • HANALL PHARMACEUTICAL COMPANY. LTDKIM, Sung WukJUN, Sung SooJO, Young GwanKOO, Ja SeongSUN, Sang Ouk
    • KIM, Sung WukJUN, Sung SooJO, Young GwanKOO, Ja SeongSUN, Sang Ouk
    • A61K31/35
    • A61K31/35A61K31/616A61K45/06A61K2300/00
    • The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
    • 本发明涉及用于预防和治疗心血管疾病的时间治疗组合药物制剂,其基于以特定时间间隔施用多种药物的原理(时间疗法)。 具体而言,组合药物制剂包含HMG-CoA还原酶抑制剂,例如辛伐他汀和阿司匹林。 由于基于给予药物的原理以一定的时间间隔开发了所谓的时间疗法,所以与单独施用和同时施用单一制剂相比,其显示出预防或治疗心血管疾病的优异效果。 此外,这是一种每日一次的剂型,可增加患者的用药依从性。 特别是,即使组合药物制剂中阿司匹林的含量降低,阿司匹林在组合药物制剂中的血小板聚集抑制效果等于现有技术中使用的阿司匹林的量,而组合药物中的阿司匹林 配方显示出抗高血压作用。 此外,时效治疗组合药物制剂允许两种彼此相互作用的药物长时间储存​​,且组合药物制剂确保两种药物的人体安全性和功效。
    • 5. 发明申请
    • N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    • N,N-二甲基咪唑二羧酸二乙酸酯,其制备方法和包含其的药物组合物
    • WO2008093984A1
    • 2008-08-07
    • PCT/KR2008/000529
    • 2008-01-29
    • HANALL PHARMACEUTICAL COMPANY. LTDKIM, Sung WukJUN, Sung SooJO, Young GwanKOO, Ja SeongKIM, Young Woong
    • KIM, Sung WukJUN, Sung SooJO, Young GwanKOO, Ja SeongKIM, Young Woong
    • A61K31/155
    • A61K31/155C07C279/26
    • The present invention relates to N,N -dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
    • 本发明涉及N,N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐,其制备方法和包含其的药物组合物,更具体地说,涉及作为结晶酸加成盐的N,N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐,其是由 使N,N-二甲基亚氨基二亚甲基二酰胺与乙酸反应,作为治疗代谢综合征的糖尿病,糖尿病,肥胖症,高脂血症,脂肪肝,冠心病,骨质疏松症,多囊卵巢综合症,癌症, 贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性,稳定性,非吸湿性,抗附着性等等的物理化学性质和低毒性方面都是优异的,因此治疗癌症并防止肌肉痛,肌肉细胞毒性和横纹肌溶解等。 的制备方法和包含其的药物组合物。